These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10442258)

  • 1. Hair loss associated with paroxetine treatment: a case report.
    Zalsman G; Sever J; Munitz H
    Clin Neuropharmacol; 1999; 22(4):246-7. PubMed ID: 10442258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alopecia due to Seroxat therapy].
    Umansky L; Dorevitch A; Sella A
    Harefuah; 2000 Apr; 138(7):547-9, 614. PubMed ID: 10883182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
    Yasui-Furukori N; Kaneko S
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hair Loss Associated with Paroxetine Use: A Case Report.
    Kurhan F; Kamış GZ
    Turk Psikiyatri Derg; 2021; 32(1):61-64. PubMed ID: 34181746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible hepatotoxicity of paroxetine in a patient with major depression.
    Helmchen C; Boerner RJ; Meyendorf R; Hegerl U
    Pharmacopsychiatry; 1996 Nov; 29(6):223-6. PubMed ID: 8956353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Narcoleptic syndrome as a possible side effect of paroxetine].
    Alonso H; Ortí-Pareja M; Jiménez-Jiménez FJ
    Rev Neurol; 2004 Dec 1-15; 39(11):1092. PubMed ID: 15597274
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of serial nightmares and oneiroid state under paroxetine for senile depression.
    Kobayashi T; Yamauchi M
    Psychogeriatrics; 2012 Mar; 12(1):54-7. PubMed ID: 22416829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate].
    Vergouwen AC; Bakker A
    Ned Tijdschr Geneeskd; 2002 Apr; 146(17):811-2. PubMed ID: 12014241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug-induced alopecia: review of the literature].
    Llau ME; Viraben R; Montastruc JL
    Therapie; 1995; 50(2):145-50. PubMed ID: 7631289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid weight gain associated with edema after use of paroxetine and venlafaxine: 2 case reports.
    Uguz F
    Clin Neuropharmacol; 2014; 37(1):34-5. PubMed ID: 24434531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.
    Yasui-Furukori N; Sato Y; Kato H; Kaneko S
    Clin Neuropharmacol; 2012; 35(1):47-8. PubMed ID: 22240860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine and galactorrhea.
    Bonin B; Vandel P; Sechter D; Bizouard P
    Pharmacopsychiatry; 1997 Jul; 30(4):133-4. PubMed ID: 9271780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
    Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
    Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ
    Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL
    Psychopharmacol Bull; 2003; 37 Suppl 1():29-41. PubMed ID: 14566199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis after paroxetine treatment.
    Ahmed R; Eagleton C
    N Z Med J; 2008 May; 121(1274):86-9. PubMed ID: 18535650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.